US2017321279A1PendingUtilityA1

Non-invasive detection of fetal genetic traits

Assignee: SEQUENOM INCPriority: Oct 16, 2003Filed: Jul 18, 2017Published: Nov 9, 2017
Est. expiryOct 16, 2023(expired)· nominal 20-yr term from priority
C12Q 1/6806C12Q 1/6883C12Q 2600/156
69
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Blood plasma of pregnant women contains fetal and (generally >90%) maternal circulatory extracellular DNA. Most of said fetal DNA contains ≦500 base pairs, said maternal DNA having a greater size. Separation of circulatory extracellular DNA of <500 base pairs results in separation of fetal from maternal DNA. A fraction of a blood plasma or serum sample of a pregnant woman containing, due to size separation (e.g. by chromatography, density gradient centrifugation or nanotechnological methods), extracellular DNA substantially comprising ≦500 base pairs is useful for non-invasive detection of fetal genetic traits (including the fetal RhD gene in pregnancies at risk for HDN; fetal Y chromosome-specific sequences in pregnancies at risk for X chromosome-linked disorders; chromosomal aberrations; hereditary Mendelian genetic disorders and corresponding genetic markers; and traits decisive for paternity determination) by e.g. PCR, ligand chain reaction or probe hybridization techniques, or nucleic acid arrays.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A fraction of a sample of the blood plasma or serum of a pregnant woman in which, as the result of said sample having been submitted to a size separation, the extracellular DNA present therein substantially consists of DNA comprising 500 base pairs or less.

Join the waitlist — get patent alerts

Track US2017321279A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.